The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

By S. Kahn. Diabetologia, 2003

2,224 citations recorded by the source corpus.

Subfields: Molecular Biology, Physiology, Surgery

View Paper: https://www.semanticscholar.org/paper/ab98b6ceb2e9a0c6783f65278ca1852f40f9598b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Ralph DeFronzo
2. F. Alsaraj
3. A. Andersson
4. R. Bergenstal
5. D. Nathan
6. P. Westermark
7. B. Ahrén
8. G. Westermark

In Physiology

1. Ralph DeFronzo
2. A. Andersson
3. D. Nathan
4. F. Alsaraj
5. C. Choi
6. Shin-Hae Lee
7. P. Westermark
8. B. Ahrén

In Surgery

1. F. Alsaraj
2. Ralph DeFronzo
3. D. Nathan
4. B. Ahrén
5. M. S. Winzell
6. Gerald I. Shulman
7. V. Samuel

Citations in the corpus

• Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol (2011, background): “The underlying changes in beta cell function have been well described [3, 4], and beta-cell mass decreases steadily during the course of type 2 diabetes [5, 6].”
• Insulin Resistance: From Mechanisms to Therapeutic Strategies (2021, background): “In the prediabetic condition, insulin levels increase to meet normal insulin requirements leading to chronic hyperinsulinemia, hyperglycemia-induced β-cell failure, and eventually to T2DM [2].”
• The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. (2004, background): “New treatment should aim at normalizing the basic defects in the disease, which are islet dysfunction in combination with insulin resistance (2).”
• Impaired Fasting Glucose and Impaired Glucose Tolerance (2007, background): “Moreover, low insulin secretion and severe insulin resistance identify individuals more likely to progress to diabetes (39).”
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2012, background): “Indeed, while matching a drug’s mechanism of action to the underlying causes of hyperglycaemia in a specific patient seems logical, there are few data that compare strategies based on this approach [109].”